Finally, while targeting hepatic ASGR1 would represent an intriguing lipid-lowering strategy for dyslipidemia thus reducing the burden of atherosclerotic cardiovascular diseases, the potential adverse effects including hepatic cardiometabolic and inflammation consequences, should be taken into consideration before starting the development of pharmacological strategies inhibiting ASGR1. Here, ASGR1 is linked to metabolic syndrome.